3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
15
Neoplasm Metastasis
5
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Carcinoma, Renal Cell
2
von Hippel-Lindau Disease
1
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Interventions
pembrolizumab
16
Bevacizumab
12
Carboplatin
10
Nivolumab
8
Pemetrexed
7
Temozolomide
6
Standard of Care
6
Exercise
6
Cetuximab
6
durvalumab
5
atezolizumab
5
Prednisone
5
Cyclophosphamide
5
abemaciclib
4
Paclitaxel
4
Doxorubicin
4
Dexamethasone
4
Cisplatin
4
Blood Specimen Collection
4
temsirolimus
3
enzalutamide
3
dostarlimab
3
daratumumab
3
cabozantinib
3
Sunitinib
3
Rituximab
3
Oxaliplatin
3
Metformin
3
Leucovorin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
palbociclib
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled